The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Safety Study of SGN-CD19A for Leukemia and Lymphoma
Official Title: A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With B-Lineage Acute Lymphoblastic Leukemia and Highly Aggressive Lymphomas
Study ID: NCT01786096
Brief Summary: This is a phase 1, open-label, dose-escalation, multicenter study to evaluate the safety and tolerability of SGN-CD19A in adult and pediatric patients with relapsed or refractory B-lineage acute lymphoblastic leukemia (B-ALL), Burkitt lymphoma or leukemia, or B-lineage lymphoblastic lymphoma (B-LBL).
Detailed Description:
Minimum Age: 1 Year
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Children's Hospital of Alabama / University of Alabama at Birmingham, Birmingham, Alabama, United States
University of Alabama at Birmingham, Birmingham, Alabama, United States
Mayo Clinic Arizona, Scottsdale, Arizona, United States
City of Hope National Medical Center, Duarte, California, United States
Mayo Clinic Florida, Jacksonville, Florida, United States
All Children's Hospital, Saint Petersburg, Florida, United States
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
Children's Healthcare of Atlanta / Emory University, Atlanta, Georgia, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
Boston Children's Hospital, Boston, Massachusetts, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Name: Eric Feldman, MD
Affiliation: Seagen Inc.
Role: STUDY_DIRECTOR